Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety, tolerability, and pharmacokinetics (PK) of a single
escalating dose and repeated doses of CN-105 in healthy adult participants. There will be
about 48 subjects, 36 active and 12 placebo.